Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis

改变镇静模式以改善严重脓毒症的脑损伤和生存率

基本信息

  • 批准号:
    8530272
  • 负责人:
  • 金额:
    $ 70.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The need for mechanical ventilation (MV) secondary to sepsis is the leading cause of admission to the intensive care unit, often necessitating sedation for patient safety and comfort. Recently, we have learned that these sedative medications contribute to iatrogenic injury, such as prolonging ventilator time and ICU length of stay and exacerbating acute brain dysfunction. This acute brain dysfunction, manifested as delirium and coma, occurs in 50%-70% of MV septic patients and is a significant contributor not only to death but also to functional and cognitive decline, which can persist for years after recovery of lung and other organ function, levying significant costs to patients and society. Despite advances in the management of acute respiratory failure and sepsis, few clinical trials have examined the effects that supportive therapies, like sedation, may have on both short- and long-term outcomes in this vulnerable population. The gamma-aminobutyric acid (GABA)-ergic benzodiazepines, in particular, have been shown to increase brain dysfunction, promote infection, and prolong MV. Therefore, the short-acting GABA-ergic sedative propofol and the alpha2 agonist dexmedetomidine are becoming widely used to sedate septic MV patients. There are only a few randomized trials, however, to guide clinicians when selecting between these and other sedatives, and none have explored the mechanisms underlying the differences in outcomes, though some data indicate that GABA-ergic and alpha2 agonist agents have very different effects on innate immunity, apoptosis, arousability, and respiratory drive. In early animal and human studies, dexmedetomidine had more anti-inflammatory effects than the GABA-ergic agents; dexmedetomidine improved bacterial clearance, whereas propofol impaired it. In addition, sedation with dexmedetomidine instead of benzodiazepines reduces delirium by 20%-30% and improves arousability, cognition, and attentiveness in ventilated patients. Alpha2 agonists induce unconsciousness at the brainstem- more akin to natural sleep-which may improve autonomic function and immunity. All these factors converge to suggest that sedation with an alpha2 agonist rather than a GABAergic agent may improve outcomes, including brain function, MV, and survival, for septic MV patients. We therefore propose the MENDS II (Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients with Acute Respiratory Failure) study, in which we will test the hypotheses that sedation of MV severely septic patients with an alpha2 agonist (dexmedetomidine) rather than a GABAergic agent (propofol) will (Aim 1A) increase days alive without delirium or coma, (Aim 1B) increase ventilator-free days, (Aim 2A) improve 90-day survival, (Aim 2B) decrease long-term cognitive impairment, and (Aim 3) reduce the pro-inflammatory cytokine cascade following sepsis. We will randomize 530 ventilated, severely septic patients requiring goal-directed sedation with dexmedetomidine or propofol, giving the study 90% power to detect a difference of 1.5 delirium/coma-free days and an absolute difference in mortality of 10% between the two groups.
描述(由申请人提供): 继发于脓毒症的机械通气(MV)需求是进入重症监护室的主要原因,通常需要镇静以确保患者的安全和舒适。最近,我们了解到这些镇静药物会导致医源性损伤,如延长呼吸机使用时间和ICU住院时间以及加重急性脑功能障碍。这种急性脑功能障碍,表现为谵妄和昏迷,发生在50%-70%的MV脓毒症患者中,并且不仅是死亡的重要因素,而且也是功能和认知下降的重要因素,其可以在肺和其他器官功能恢复后持续数年,给患者和社会带来重大成本。尽管在急性呼吸衰竭和脓毒症的管理方面取得了进展,但很少有临床试验研究了支持性治疗(如镇静)对这一脆弱人群的短期和长期结局的影响。特别是γ-氨基丁酸(GABA)能的苯二氮卓类药物,已被证明会增加脑功能障碍,促进感染,并延长MV。因此,短效GABA能镇静剂丙泊酚和α 2激动剂右美托咪定正被广泛用于使脓毒症MV患者镇静。然而,只有少数随机试验指导临床医生在这些和其他镇静剂之间进行选择,并且没有探索结果差异的潜在机制,尽管一些数据表明GABA能和α 2激动剂对先天免疫,细胞凋亡,唤醒能力和呼吸驱动有非常不同的影响。在早期的动物和人体研究中,右美托咪定比GABA能药物具有更强的抗炎作用;右美托咪定可提高细菌清除率,而丙泊酚则会降低细菌清除率。此外,用右美托咪定代替苯二氮卓类药物进行镇静可减少20%-30%的谵妄,并改善通气患者的唤醒能力、认知能力和注意力。α 2激动剂在脑干诱导无意识-更类似于自然睡眠-这可能改善自主神经功能和免疫力。所有这些因素共同表明,与GABA能药物相比,α 2激动剂镇静可能改善脓毒症MV患者的结局,包括脑功能、MV和生存率。因此,我们建议MENDS II(最大化镇静效果并降低急性呼吸衰竭脓毒症患者的神经功能障碍和死亡率)研究,在该研究中,我们将检验α 2激动剂对MV严重脓毒症患者的镇静作用(右美托咪定)而非GABA能药物(丙泊酚)将(目的1A)增加无谵妄或昏迷的存活天数,(目的1B)增加无呼吸机天数,(目的2A)改善90天生存率,(目的2B)减少长期认知障碍,和(目的3)减少脓毒症后的促炎细胞因子级联。我们将随机分配530例需要右美托咪定或丙泊酚目标导向镇静的通气、严重脓毒症患者,使研究有90%的把握度检测两组之间1.5个无谵妄/无昏迷天数的差异和10%的死亡率绝对差异。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pratik Pandharipande其他文献

Pratik Pandharipande的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pratik Pandharipande', 18)}}的其他基金

Maximizing Efficacy of Goal-Directed Sedation to Reduce Neurological Dysfunction in Mechanically Ventilated Infants and Children Study (mini-MENDS)
在机械通气婴儿和儿童研究中最大限度地提高目标导向镇静效果以减少神经功能障碍 (mini-MENDS)
  • 批准号:
    10685311
  • 财政年份:
    2021
  • 资助金额:
    $ 70.26万
  • 项目类别:
Maximizing Efficacy of Goal-Directed Sedation to Reduce Neurological Dysfunction in Mechanically Ventilated Infants and Children Study (mini-MENDS)
在机械通气婴儿和儿童研究中最大限度地提高目标导向镇静效果以减少神经功能障碍 (mini-MENDS)
  • 批准号:
    10274781
  • 财政年份:
    2021
  • 资助金额:
    $ 70.26万
  • 项目类别:
Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis
改变镇静模式以改善严重脓毒症的脑损伤和生存率
  • 批准号:
    8693008
  • 财政年份:
    2012
  • 资助金额:
    $ 70.26万
  • 项目类别:
Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis
改变镇静模式以改善严重脓毒症的脑损伤和生存率
  • 批准号:
    8894072
  • 财政年份:
    2012
  • 资助金额:
    $ 70.26万
  • 项目类别:
Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis
改变镇静模式以改善严重脓毒症的脑损伤和生存率
  • 批准号:
    9269389
  • 财政年份:
    2012
  • 资助金额:
    $ 70.26万
  • 项目类别:
Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis
改变镇静模式以改善严重脓毒症的脑损伤和生存率
  • 批准号:
    9125859
  • 财政年份:
    2012
  • 资助金额:
    $ 70.26万
  • 项目类别:
Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis
改变镇静模式以改善严重脓毒症的脑损伤和生存率
  • 批准号:
    8371719
  • 财政年份:
    2012
  • 资助金额:
    $ 70.26万
  • 项目类别:

相似海外基金

Optimizing Time-Limited Trials of Mechanical Ventilation in Acute Respiratory Failure: A Mixed Methods Observational Study
优化急性呼吸衰竭机械通气的限时试验:混合方法观察研究
  • 批准号:
    10633823
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
Novel Digital Methods to Evaluate Functional and Pulmonary Outcomes following Pediatric Acute Respiratory Failure
评估小儿急性呼吸衰竭后功能和肺部结果的新型数字方法
  • 批准号:
    10724042
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
Use of Inter-Hospital Transfer Services in Critical Illness and Acute Respiratory Failure
在危重疾病和急性呼吸衰竭中使用医院间转运服务
  • 批准号:
    10739060
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
Strengthening implementation science in Acute Respiratory Failure using multilevel analysis of existing data
利用现有数据的多级分析加强急性呼吸衰竭的实施科学
  • 批准号:
    10731311
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
Identifying patient subgroups and processes of care that cause outcome differences following ICU vs. ward triage among patients with acute respiratory failure and sepsis
确定急性呼吸衰竭和脓毒症患者在 ICU 与病房分诊后导致结局差异的患者亚组和护理流程
  • 批准号:
    10734357
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
Respiratory Drive in Acute Respiratory Failure
急性呼吸衰竭中的呼吸驱动
  • 批准号:
    10637245
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
Temporal trends in quality indicators of palliative care for patients with chronic illness hospitalized with acute respiratory failure
因急性呼吸衰竭住院的慢性病患者姑息治疗质量指标的时间趋势
  • 批准号:
    10622756
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
Health expectations after acute respiratory failure in survivor-care partner dyads
幸存者护理伙伴二人组急性呼吸衰竭后的健康期望
  • 批准号:
    10732929
  • 财政年份:
    2023
  • 资助金额:
    $ 70.26万
  • 项目类别:
Financial Hardship among Patients with Acute Respiratory Failure and their Family Member Caregivers: Understanding the Impact on Patient- and Family- Centered Outcomes
急性呼吸衰竭患者及其家庭成员护理人员的经济困难:了解对以患者和家庭为中心的结果的影响
  • 批准号:
    10413457
  • 财政年份:
    2022
  • 资助金额:
    $ 70.26万
  • 项目类别:
Association of patient characteristics and antibiotic timing with the development of acute respiratory failure in hospital-acquired sepsis
患者特征和抗生素使用时机与医院获得性脓毒症急性呼吸衰竭发展的关系
  • 批准号:
    10313769
  • 财政年份:
    2022
  • 资助金额:
    $ 70.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了